Clinical Trial Update: A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection [Phase 2]

View source ↗

Summary

Phase 2 multicenter study assessing depth and duration of Hepatitis B surface antigen reduction after ARC-520, with or without Entecavir, in adults with chronic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• ARC-520
• ENTECAVIR (ENTECAVIR)

Snippet

Sponsor: Arrowhead Pharmaceuticals | Conditions: Hepatitis B, Chronic | Phase 2 | Status: TERMINATED | Results posted: 2019-07-05